Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC grew its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 12.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,274,482 shares of the medical device company's stock after purchasing an additional 138,263 shares during the quarter. Stephens Investment Management Group LLC owned approximately 1.95% of Tandem Diabetes Care worth $54,051,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. BNP Paribas Financial Markets raised its stake in Tandem Diabetes Care by 1,481.5% during the first quarter. BNP Paribas Financial Markets now owns 145,812 shares of the medical device company's stock worth $5,163,000 after purchasing an additional 136,592 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Tandem Diabetes Care in the first quarter valued at $540,000. Vanguard Group Inc. grew its position in Tandem Diabetes Care by 0.4% during the first quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company's stock valued at $249,732,000 after acquiring an additional 30,664 shares during the period. SG Americas Securities LLC purchased a new position in shares of Tandem Diabetes Care in the 1st quarter worth about $5,227,000. Finally, Quantbot Technologies LP acquired a new position in shares of Tandem Diabetes Care in the 1st quarter valued at about $710,000.

Analyst Ratings Changes

Several research firms recently commented on TNDM. Morgan Stanley restated an "equal weight" rating and issued a $45.00 price target on shares of Tandem Diabetes Care in a report on Monday, September 23rd. Canaccord Genuity Group began coverage on shares of Tandem Diabetes Care in a report on Thursday, August 8th. They set a "buy" rating and a $57.00 target price on the stock. Wells Fargo & Company increased their price target on Tandem Diabetes Care from $50.00 to $55.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. Canaccord Genuity Group started coverage on Tandem Diabetes Care in a research note on Thursday, August 8th. They set a "buy" rating and a $57.00 price objective on the stock. Finally, Royal Bank of Canada assumed coverage on Tandem Diabetes Care in a report on Wednesday, October 2nd. They set an "outperform" rating and a $65.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Tandem Diabetes Care has an average rating of "Moderate Buy" and a consensus target price of $55.13.

Tandem Diabetes Care Stock Performance

Shares of TNDM stock traded up $0.54 on Friday, hitting $31.91. 906,252 shares of the stock traded hands, compared to its average volume of 1,583,125. The company's fifty day moving average is $40.14 and its 200 day moving average is $41.77. Tandem Diabetes Care, Inc. has a 1-year low of $13.82 and a 1-year high of $53.69. The company has a market capitalization of $2.09 billion, a PE ratio of -15.01 and a beta of 1.33. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.05 and a quick ratio of 2.38.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The medical device company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. Tandem Diabetes Care had a negative net margin of 17.15% and a negative return on equity of 41.54%. The company had revenue of $221.90 million for the quarter, compared to the consensus estimate of $205.63 million. During the same period last year, the firm posted ($0.30) EPS. The company's revenue for the quarter was up 13.3% on a year-over-year basis. On average, equities research analysts predict that Tandem Diabetes Care, Inc. will post -1.76 earnings per share for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.